Hls Therapeutics (TSE:HLS) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
HLS Therapeutics Inc. has announced findings from the REDUCE-IT clinical trial, revealing that their drug VASCEPA significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with high or low Lipoprotein(a) levels. The analysis, which also featured in the Journal of the American College of Cardiology, shows that VASCEPA offers a consistent treatment benefit across different patient subgroups, regardless of their baseline LDL-C or triglyceride levels.
For further insights into TSE:HLS stock, check out TipRanks’ Stock Analysis page.